Patents by Inventor Irene Chernova

Irene Chernova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7709214
    Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: May 4, 2010
    Assignees: Dana-Farber Cancer Institute, Inc., Genetics Institute, LLC
    Inventors: Gordon J. Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive R. Wood
  • Patent number: 7432059
    Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. The invention further provides methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1-mediated signal. Diagnostic and treatment methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: October 7, 2008
    Assignees: Dana-Farber Cancer Institute, Inc., Genetics Institute, LLC, Brigham and Women's Hospital
    Inventors: Gordon Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive Wood, Yvette Latchman, Arlene H. Sharpe
  • Publication number: 20080118511
    Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 20, 2007
    Publication date: May 22, 2008
    Applicants: Dana-Farber Cancer Institute, Inc., Genetics Institute LLC
    Inventors: Gordon Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive R. Wood
  • Publication number: 20020164600
    Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 28, 2001
    Publication date: November 7, 2002
    Inventors: Gordon Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive Wood
  • Publication number: 20020110836
    Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 28, 2001
    Publication date: August 15, 2002
    Inventors: Gordon Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive Wood, Yvette Latchman, Arlene H. Sharpe